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Objectives:
 
 Despite optimal pharmacological treatment
a large proportion of patients with atrial fibrillation
(Afib) are not arrhythmia-free, and remain at risk for
complications such as stroke and cardiac morbidity. If
first-line treatment fails, most patients receive second-
line pharmacological treatment. The emergence of new
technologies aimed at restoring and maintaining sinus
rhythm, such as catheter ablation techniques, has in-
creased the interest in the economic aspects of second-line
pharmacological treatment. The objective was therefore
to calculate the 5-year direct medical costs of second-
line pharmacological management of paroxysmal and
persistent Afib in France.
 
Methods:
 
 The analysis was based on clinical and eco-
nomic literature and the input of cardiologists-electro-
physiologists. The analysis included probabilities of
stroke, sudden cardiac death, other cardiac and noncar-
diac death, direct medical costs of drugs, follow-up and
complications from the healthcare payer’s perspective.
Included treatment strategies were (1) rhythm control
with class Ic and III antiarrhythmics and (2) rate con-
trol, consisting of digoxin combined with a beta-blocker
or calcium antagonist. Both strategies included aspirin
or anticoagulation therapy.
 
Results:
 
 The average total 5-year cost of Afib was
16,539 Euro (FF 108,486) per patient. The result was
stable to sensitivity analysis on incidence of stroke and
type of stroke prevention. The main cost drivers were
follow-up visits and hospitalizations and the cost of
congestive heart failure. Both items being subject to
some variation, they were submitted to sensitivity anal-
ysis showing minimal 5-year costs still over 14,483
Euro (FF 95,000).
 
Conclusions:
 
 Afib management places high demands on
medical resources mainly through its complications and
comorbidity.
 
Keywords:
 
 analytical model, atrial fibrillation, cost anal-
ysis, pharmacological treatment.
 
Introduction
 
Atrial fibrillation is the most frequently encoun-
tered arrhythmia in clinical practice [1], with a
prevalence increasing with age to approximately
5% over the age of 60 years. Not only does it cause
symptoms prompting patients to seek medical care,
it also carries long-term risks. It predisposes the
patient to embolic stroke, impaired cardiac func-
tion and cardiac mortality [2]. Furthermore, ap-
proximately 50% of patients [3] with atrial fibril-
lation also suffer from congestive heart failure,
which has been suggested to enhance the risk of
stroke [3,4] and mortality [5].
Atrial fibrillation merits medical as well as eco-
nomic attention given: 1) the high prevalence of
the disease; 2) the remaining controversies regard-
ing optimal medical management; and 3) the emer-
gence of new technologies, which may have differ-
ent effects on health but also different economic
characteristics [6].
Apart from treating symptoms, the ultimate
goal of treating atrial fibrillation is to prevent long-
term medical risks associated with atrial fibrilla-
tion. The currently available antiarrhythmic drugs
can reduce symptoms, but in the majority of pa-
tients they fail to completely control the arrhyth-
mia and subsequent long-term medical risks.
With most antiarrhythmic drugs, a recurrence
rate of 50% at one year is observed. With pro-
grammed serial administration of antiarrhythmic
drugs, up to 63% of patients with chronic atrial fi-
brillation have been reported to be free of arrhyth-
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mia at 2 years [7]. However, a large proportion of
patients continue to carry the long-term risk of
complications associated with disturbed atrial func-
tion [4]. This proportion may be even larger when
taking into account asymptomatic episodes that oc-
cur in significant numbers of patients, even when
clinically controlled with antiarrhythmic drugs [8].
Given the limited efficacy of antiarrhythmic
drugs to restore and maintain sinus rhythm, an al-
ternative strategy, rate control, is often applied.
This consists of solely controlling ventricular rate
and accepting the atrial arrhythmia. This alterna-
tive approach is effective in symptom reduction
and cardiac function improvement.
To address the embolic risk, present in both
strategies, anticoagulation or aspirin therapy is rec-
ommended in combination with the antiarrhyth-
mic and/or rate-controlling drugs.
In summary, two main treatment strategies can
be considered: 1) rhythm control, with class Ic and
III antiarrhythmics; and 2) rate control with digoxin
therapy in combination with a beta-blocker or a
calcium antagonist. Both strategies are supplemented
with either aspirin or anticoagulation therapy.
Considering the morbidity and mortality as-
sociated with atrial fibrillation despite currently
available therapies, and the long-term, often mul-
tiple-drug treatment, atrial fibrillation results in a
significant burden on health care budgets. For in-
stance, atrial fibrillation causes more days of hos-
pitalization in the United States than all ventricu-
lar arrhythmias combined [9]. In addition, the
hospitalizations for late complications, such as
stroke, need to be taken into account.
Currently, the cost of second-line pharmaceuti-
cal treatment of atrial fibrillation (i.e., as from re-
currence after first line drugs) is unknown. Yet,
given the complex patient risk profile, this is an
area of concern for clinicians. Alternatives to the
second-line pharmacological treatment of atrial fi-
brillation, such as catheter ablation techniques,
are emerging and the economic impact of second-
line pharmacological management of atrial fibril-
lation may become of interest in relation to these
new techniques. In such a situation, incidence
based cost-of-illness models are of use, since they
can serve as a reference for later comparison of
new interventions.
The purpose of this analysis was therefore to
calculate the total direct health care costs associ-
ated with second line pharmacological treatment
of paroxysmal and persistent atrial fibrillation,
from the health care payer’s perspective. France
was chosen as the country of interest.
 
Methods
 
The Cost Analytical Model
 
A 5-year decision analytical model [10] reflecting
second-line pharmacological rhythm control as
well as pharmacological rate control in patients
with paroxysmal or persistent atrial fibrillation
was developed. Paroxysmal atrial fibrillation was
defined as self-terminating episodes and persistent
atrial fibrillation as episodes requiring cardiover-
sion.
The model simulates the natural history of atrial
fibrillation, taking into account the risk of stroke,
which depends on the administration of anticoag-
ulation or antiaggregation therapy, the risk of
sudden cardiac death which increases with the use
of some antiarrhythmics [11], and the risk of
other cardiac and noncardiac mortality depending
on comorbidity. Such a model allows inclusion of
all relevant outcomes, together with the time to
events. The time horizon of five years was selected
because it is sufficiently long for incorporating the
relevant outcomes. Longer time horizons would
be subject to more uncertainty with regard to the
future medical management in these patients.
The direct costs implemented in the model in-
clude costs of pharmacological treatment, costs of
medical follow-up and costs of preventing or treat-
ing complications such as stroke or major hemor-
rhage, all from the health care payer’s perspective
(Sécurité Social).
The model calculates the estimated average costs
of second-line pharmacological management of
atrial fibrillation, and is shown in Fig. 1. The clin-
ical probabilities in the model are discussed in next
paragraph.
At baseline, a distinction was made between two
subgroups: patients with decreased cardiac func-
tion (NYHA class 2 or more), and patient with
normal cardiac function (NYHA class 
 

 
 1), due
to the different prognosis and medical manage-
ment.
In the current analysis a combination of class Ic
and class III antiarrhythmic drugs, the most fre-
quently cited therapy by French cardiologists (see
further), was applied as rhythm control strategy.
Rhythm control was cited by an expert consensus
panel (see further) as the most common practice
(71.4%).
For rate control, based on recent recommenda-
tions [5,9,12], digoxin was applied combined with
beta-blocker or calcium antagonist therapy de-
pending on cardiac performance. Furthermore, it
was assumed that once second-line antiarrhythmic
 Cost of Atrial Fibrillation
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therapy had been stopped it was not replaced by
another antiarrhythmic drug, but that treatment
was switched to rate control.
Thromboembolic prevention was added to rhythm
or rate control. In the base-case analysis, based on
the results from an expert consensus panel (see
further), 66.5% of patients are assumed to be
treated with anticoagulation therapy, all other pa-
tients with aspirin. In reality it is likely that a lower
rate of anticoagulation treatment will be observed,
for example due to contra-indications, which are
seen in, on average, 40% of patients screened for
clinical trials [13] or as a consequence of inconve-
nience of intense monitoring associated with anti-
coagulation treatment. Indeed, surveys have shown
that many patients with atrial fibrillation (up to
70%) are not receiving preventive treatment for
stroke [14]. This difference between reported and
real use of anticoagulation was made subject to a
sensitivity analysis (see below).
Figure 1 Decision analytical tree, including applied probabilities in patients without cardiac impairment; CHF “clones” are ex-
act copies of subtrees, however, with other probabilities and costs. Afib, Atrial fibrillation; AC, Anticoagulation; CHF, Conges-
tive heart failure; AA, Anti-arrhythmics.
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Clinical Data Applied in the Model
 
Congestive Heart Failure.
 
The prevalence of con-
gestive heart failure at baseline was based on the
data from the Framingham study, in which 50%
of patients with atrial fibrillation also suffered
from congestive heart failure [3].
 
Stroke.
 
The risk of stroke is similar in patients
with paroxysmal or persistent atrial fibrillation [15]
Multivariate analysis of pooled data from clinical
trials did not show a significant difference in stroke
risk associated with the presence or absence of
heart failure. Nor has a significant effect of anti-
arrhythmic therapy on the incidence of thrombo-
embolism been proven [2]. This question will in fact
be answered by the prospective AFFIRM study com-
paring mortality between rate control and rhythm
control [16], the results of which will not become
available for several years. Therefore, throughout
the model, the stroke rate was calculated by ap-
plying the risk reductions attributable to anticoag-
ulation or aspirin therapy to the rate of stroke in
the untreated population. The annual rate of stroke
in the absence of anticoagulation or aspirin ther-
apy reported by the Atrial Fibrillation Investiga-
tors in 1994 was 4.5%. The risk reduction with
warfarin, consistently found in multiple studies,
was 68% [17]. A reduction of stroke risk by aspi-
rin therapy has also been reported but this has
been less consistent, with reductions ranging from
18 to 54%. An average risk reduction of 36% was
reported from pooled analyses [17].
Approximately 45% of strokes are major, asso-
ciated with a remaining residual deficit [17]. Twenty-
eight day mortality after stroke in patients with
atrial fibrillation is approximately 19.5% [18].
The risk of stroke after a previous stroke was two
times higher than the primary risk [1].
 
Sudden Cardiac Death.
 
Several antiarrhythmic
drugs have been shown to increase the risk of sud-
den cardiac death, through a type of ventricular
arrhythmia known as 
 
torsades de pointes.
 
 There
has been great concern with regard to the use of
class I antiarrhythmics since the CAST study was
published, showing an increased incidence of sud-
den cardiac death associated with the treatment
with flecainide and encainide in postmyocardial
infarction patients [19]. However, in patients with-
out heart disease, class Ic drugs associated ventric-
ular pro-arrhythmia or sudden cardiac death is vir-
tually absent [20]. Hence, only in case of cardiac
impairment the use of class I c antiarrhythmics
should be avoided. In this patient population ami-
odarone is the drug of choice [12]. With amio-
darone the risk of sudden arrhythmic death ap-
pears to be 
 

 
1% [21].
In the SPAF study the rate of sudden death in
case of normal cardiac function was 1.5% in 1.3
years of follow-up and was independent of anti-
arrhythmic drug use [22]. In our economic model
this risk was applied to both rate control and rhythm
control, in the absence of cardiac failure. In the
same study, patients with cardiac failure showed a
sudden death risk of 5%, but in the large majority
of patients the antiarrhythmic therapy consisted of
quinidine, a drug not considered in our model (see
below). A retrospective analysis by Dries et al.
(1998) in a population managed for 80% by rate
control and of which two thirds had NYHA clas-
sification I, and one third had NYHA classifica-
tion II, indicated slightly higher rates of arrhythmic
deaths (see Table 1) [23]. The results of this analy-
sis were applied in the model for patients with heart
failure on rate control strategy. Note that in Dries
et al. 22% of patients had heart failure class III/IV
and 78% had heart failure class I/II. A weighted av-
erage for both groups was calculated.
Patients with heart failure and receiving rhythm
control therapy were assumed to be treated with
amiodarone without additional class Ic antiarrhyth-
mic, according to guidelines. In patients with severe
congestive heart failure treated with amiodarone,
the 2-year sudden death free survival was reported
 
Table 1
 
Probabilities of sudden cardiac death* for different patient types
 
Population Reported risk 5-year probability of sudden death Reference
No CHF; AA 1.5%/1.3y 0.06 [22]
CHF NYHA III-IV 8.4%/2.78y 0.14 [23]
CHF NYHA I-II 4.2%/2.78y 0.07 [23]
CHF 0.085 Weighted average:
0.14 
 
 
 
0.22 
 
 
 
0.07 
 
 
 
0.78
CHF NYHA III-IV–AA (amiodarone) 16%/2y 0.34 [24]
CHF; AA 0.129 Weighted average:
0.22 
 
 
 
0.34 
 
 
 
0.78 
 
 
 
0.07
 
*Defined as arrhythmic death.
AA, anti-arrhythmic drugs; CHF, congestive heart failure.
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to be 84% [24]. For patients with mild to moderate
heart failure the sudden death rate (0.07) from Dries
et al. was also applied to amiodarone-treated pa-
tients, considering the low risk observed with this
compound. Again, a weighted average for both
groups was calculated. The results of calculations
are presented in Table 1.
 
Other Death.
 
The rate of other deaths was calcu-
lated as overall mortality minus sudden cardiac
death and death due to stroke. For patients with
congestive heart failure, the risk of other death
was based on the data from the SOLVD preven-
tion (NYHA I-II) and treatment (NYHA III-IV)
populations [23] and applied to the respective
populations. For patients with normal cardiac func-
tion we used the overall mortality from the SPAF
trial. During a follow-up of 1.3 years, 89 deaths
occurred in a cohort of 1330 patients. There were
no fatal strokes [25].
The results of the calculations regarding other
death are presented in Table 2.
 
Adverse Drug Reactions.
 
Only those adverse drug
reactions requiring medical action according to the
opinion of the expert panel were taken into account
for the analysis. Minor events were not included, al-
though they may induce some medical resource con-
sumption. On the other hand, discontinuation rates
as a consequence of adverse drug reactions were
derived from the clinical literature, and therefore in-
clude cessation due to all types of adverse events.
Clinical trials have shown that anticoagulation
therapy, when targeted at an INR between 2 and
3, is associated with a 1–3% annual incidence of
major hemorrhage [17,26]. With aspirin therapy,
the major bleeding rate is 1% per year, an inci-
dence comparable to placebo [9]. These clinical
trial rates were applied in the model as a conserva-
tive estimate, but it must be noted that in actual
clinical practice the rate of major hemorrhage with
anticoagulation treatment may be double compared
to controlled clinical trial settings [25]. A sensitiv-
ity analysis was performed to test the conse-
quences of this difference.
In case of major hemorrhage with anticoagula-
tion therapy, the latter is permanently discontin-
ued in approximately 43% of patients. We assume
that these patients are transferred to aspirin pro-
phylaxis. In another 50% of patients however, an-
ticoagulation therapy is temporarily stopped, ac-
cording to the expert panel, for an estimated
duration of six weeks. This is in line with data from
literature (Eckman et al. 1998) [27].
Flecainide leads to cardiac as well as noncar-
diac events. Class Ic antiarrhythmics can convert
atrial fibrillation into atrial flutter in approximately
5% of the cases [12]. The most frequently encoun-
tered noncardiac events are, usually not life-threat-
ening, adverse reactions of the central and periph-
eral nervous system. The discontinuation rate due
to adverse events was 22.9% during the first treat-
ment year in a small study comparing flecainide to
propafenone [28].
Amiodarone has a low risk of arrhythmia and
sudden cardiac death but it can induce serious side
effects when high dosages are used, which are
needed in the treatment of ventricular arrhythmias.
In supraventricular tachycardia however, lower dos-
ages have proven to be both efficacious and safe [1].
The most frequently encountered adverse events
are thyroid dysfunction and the development of
corneal deposits, observed in 5.7% of patients
over a period of 12 months [29], and reported by
the expert panel to occur in on average 24% of
patients over the total period. The latter figure
was applied in the model. The annual discontinua-
tion rate with amiodarone is 6.32% [1], a figure
that was applied in the model.
 
Resource Utilization.
 
The medical practice asso-
ciated with rhythm and rate control in patients
with paroxysmal or persistent atrial fibrillation
was determined through a 3-round Delphi consen-
sus procedure [30], based on the expert input of
nine French cardiologists specialized in cardiol-
 
Table 2
 
Probabilities of overall mortality and other death* for different patient types
 
Patient population Variable Reported information 5 year probability Reference
NYHA III-IV Other death 33%/2.78 y 0.49 [23]
NYHA I-II Other death 14.5%/2.78 y 0.24 [23]
CHF Other death 0.295 Weighted average:
0.22
 

 
0.49
 

 
0.78
 

 
0.24
No CHF Overall mortality 6.7%/1.3 y 0.23 [22]
No CHF Other death 0.17 Calculated: 0.23–0.06
 
*Non-stroke, non-arrhythmic death.
CHF, congestive heart failure.
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ogy-electrophysiology. Indeed, as pharmacological
treatment frequently fails to satisfactorily control
the arrhythmia, patients are often referred to elec-
trophysiologists for management advice or inter-
vention. Therefore, cardiologists with specializa-
tion in electrophysiology were selected for reporting
on the medical management of these patients. The
questions referred to the medical practice associ-
ated with the treatment of patients with atrial fi-
brillation: prescribed drugs, treatment of adverse
drug reactions, frequency of follow-up visits, an-
nual testing schedules, and frequency of unplanned
visits related to the arrhythmia. The experts were
asked in the third round to add the uncertainty
surrounding the group answers. These were ap-
plied in a sensitivity analysis (see further).
Each question was asked separately for differ-
ent patient categories. These categories result from
combining either rhythm control or rate control
on the one hand with either anticoagulation ther-
apy or antiaggregation therapy on the other. Fur-
thermore, for each of these groups, patients with
and without cardiac impairment were considered
separately. The results of the Delphi consensus
panel in terms of resource use and annual costs
are shown in Tables 3 and 4.
It was assumed, based on the expert opinion,
that all patients with persistent atrial fibrillation
treated with antiarrhythmic drugs who suffered re-
current atrial fibrillation, were cardioverted only
once. Assuming optimal anticoagulation prior to
the procedure, each cardioversion was attributed
an embolic risk of 0.8% [2]. In normal clinical
practice, the risk of recurrence is estimated at 82%
after 5 years [9]. The recurrence rate of atrial fibril-
lation with serial drug therapy was 37% in 2 years
[9] and 73% at 4 years [12]. We applied therefore
 
Table 3
 
Average total costs of adverse drug reactions in FF
 
5-year
probability N items
Unit
cost
Total
cost (FF)
Amiodarone
Thyroid dysfunction 0.237
Hospital rate 0.22 7.4 days 2000 772
*Thyroid suppl. 0.57 172.5 0.82 19
 
†
 
Fct tests (N/y) 1.00 2.22 234 123
 
§
 
Bradycardia 0.013
 
‡
 
Hosp 0.224 5.5 days 2000 32
Flecainide
Proarrhythmia 0.05
Hosp 0.75 4.75 days 2000 356
Monitoring 0.7 3 516.6 54
Digoxin
Overdose 0.028
Hosp 0.263 6.43 days 2000 95
Beta-blocker
 

 
Hypotension 0.014
Hosp 0.263 5.29 days 2000 39
 
*Thyroid hormone supplement.
 
†
 
Thyroid function tests including TSH 
 

 
 T3 or T4.
 
§
 
Rates were derived from the expert consensus panel.
 
‡
 
Hospitalization.
 

 
Revert to atrial flutter.
FF, French francs.
 
Table 4
 
Annual follow-up costs in FF including basic testing schedules and GP, cardiologist and hospital visits, based on the 
results of the expert consensus study
 
Tests (N/y) AA
 

 
antico AA
 

 
aspirin RC
 

 
antico RC
 

 
aspirin
INR 14 0 14 0
ECG 3.11 2.63 3.11 2.63
Holter monitoring 1.06 0.69 0.15 0.3
Echocardiography 0.67 0.73 0.67 0.73
Exercise testing 0.05 0.1 0.05 0.1
Thyroid function 0.03 0 0.03 0
Digoxin levels 0 0 0.28 0.28
Annual costs (FF) 1,761 1,082 1,291 916
Visits No CHF (N/y)
GP 6.6 5.56 7.44 5.67
Spec 2.6 2.11 2 1.67
Hosp 1.4 0.5 0.69 0.76
Annual costs (FF) 4,391 2,315 2876 2,706
Visits CHF (N/y)
GP 11.22 10.14 10.89 8.13
Spec 3.89 3.5 3 2.75
Hosp 5d 4.14d 4.13d 3.57d
Annual costs (FF) 12,535 10,566 10,472 8,955
Unscheduled visits (N/y)
Cardiologist 0.99 0.99 0.39 0.39
Hospital (days) 2.01d 2.01d 0.49d 0.49d
Annual costs (FF) 4,333 4,333 1,098 1,098
 
INR, international normalized ratio; ECG, electrocardiogram; FF, French francs; CHF, congestive heart failure; d, days; N/y, Number/year; GP, general practitioner
visit; Spec, Specialist visit; Hosp, Hospitalization.
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an average of 73% of patients requiring at least
one cardioversion during the 5-year model.
 
Unit Costs.
 
We applied 1998 unit costs taking the
health care payer perspective (Table 5a, 5b). Fu-
ture costs were discounted at 3%. Drug costs were
based on the public prices from Media-Vidal, 1998
[31], and by taking into account the respective re-
imbursement levels. Costs of medical interventions
and tests were derived from official listings by the
UCANSS [32]. The average costs of major hemor-
rhage and stroke have been investigated from pre-
vious economic evaluations (Table 6) [33]. The
costs of other adverse drug reactions such as thy-
roid dysfunction with amiodarone were based on
the associated resource consumption reported by
the expert panel.
In France on average 1,600,000 days are spent
in hospital for congestive heart failure, and 6 bil-
lion FF is spent annually on ambulatory care for
congestive heart failure [34]. The annual cost per
patient, based on a prevalence of 517,880 patients
[34], was calculated at 2724 Euro (FF 17,870). To
avoid overlap, we subtracted from this figure the
costs associated with atrial fibrillation. About 10%
of heart failure patients have atrial fibrillation
(SOLVD [35]). In those patients, we calculated
that the cost of atrial fibrillation management rep-
resents 56.6%. Hence, the corrected figure for
heart failure is equal to 17,870 minus 5.6% (i.e.,
10% 
 

 
 56.6%) 
 

 
 16,859 FF.
 
Results
 
Base Case Results
 
The results were calculated by assigning the rele-
vant costs to each outcome in the model and mul-
tiplying them with the probability of that outcome.
This was performed using a decision analytical
software (DATA-TreeAge 3.5). The resulting total
expected cost of 5-year second-line management
of atrial fibrillation was estimated at 16,042 Euro
(FF 105,230). The cost breakdown is shown in
Table 7. Clearly, the cost of atrial fibrillation re-
lated to physicians and hospitalizations represent
the major part of the total costs, followed by the
costs associated with heart failure.
 
Sensitivity Analyses
 
As mentioned before, it is likely that our model
overestimated the rate of anticoagulation com-
pared to the real life situation. Therefore we inves-
tigated the influence on the overall results of vary-
ing the prescription rate of anticoagulation from
 
Table 5a
 
Unit costs for medication derived from 
MediaVidal, 1998 [31]
 
Substance Unit Dose N/pack
Costpack
(FF)
Fluindione 20 mg 30 25.4
Warfarin 10 mg 25 28.2
Acenocoumarol 1 mg 20 8.1
Aspirin 500 mg 20 15.1
Digoxin 0.25 mg 30 18.3
Thyroid substitution 150 mg 50 27.2
Flecainide 100 mg 30 108.8
Amiodarone 200 mg 30 72.6
Beta blocker (atenolol) 100 mg 28 43.9
Ca antagonist (Verapamil) 120 mg 60 57
 
Table 5b
 
Unit costs for tests, investigations and
physician visits
 
Unit costs tests/interventions CODE Unit cost FF Source
Thyroid function tests* B130 234 [32]
Digoxin levels B70 126 [32]
INR B20 36 [32]
ECG K 6.5 82 [32]
Holter K41 516 [32]
Echocardiogram K50 630 [32]
Exercise test K40 504 [32]
GP visit C 115 [32]
Spec visit CsC 320 [32]
Cardioversion 5,600 GHM/iSA
 
†
 
*TSH 
 

 
T4 or T3.
 
†
 
Groupes Homogénes de Maladies, France, 1998.
FF, French francs; INR, international normalized ratio; ECG, electrocardio-
gram; GP, General practitioner visit; Spec, Specialist visit.
 
Table 6
 
Costs of events, obtained from previous 
economic studies
 
Adverse event Average cost (FF) Source
Minor stroke–acute event 26,925 [33]
Major stroke–acute event 57,417 [32]
Stroke–follow-up per 6m 39,149 [32]
Cerebral bleeding 26,925 [32]
GI bleeding 19,425 [32]
Congestive heart failure per year* 16,859 [34]
 
*Corrected for double counting.
FF, French francs; m, months; GI, gastrointestinal.
 
Table 7
 
Estimated breakdown of 5-year management costs
 
Items
Total costs
(FF)
Total costs
(Euro)
Drugs 11,315 1,725
Tests 5,798 884
Stroke 10,947 1,669
CHF 32,754 4,993
Physicians and hospitalization 42,496 6,478
Cardioversion 678 103
Sudden death 1,242 189
Total cost 105,230 16,042
 
FF, French francs; CHF, Congestive heart failure.
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30 to 70% of the patient population. The total av-
erage costs ranged from 15,759 Euro (103,374
FF) to 16,069 Euro (105,408 FF) which is a rather
modest change. In other words, the average 5-year
cost of atrial fibrillation decreases only slightly by
reducing the proportion of patients on anticoagu-
lation therapy. This can be explained by higher
therapy costs in addition to clinical follow-up cost
associated with anticoagulation treatment com-
pared to aspirin therapy.
Since there is no consensus as to whether aspi-
rin significantly reduces the stroke risk, this vari-
able was also analyzed at a range from 18% to
54%. Total costs thereby varied from 16,259 Euro
(106,653 FF) to 15,825 Euro (103,807 FF).
The cost of stroke was derived from previous
reports [33]. An analysis based on the population
from the Copenhagen Stroke Study [36] resulted
in a 30% higher cost than the current French anal-
ysis related to acute stroke. Therefore a sensitivity
analysis was performed. Reducing and increasing
the cost of major stroke by 30% resulted in total
5-year costs, respectively, 15,555 Euro (102,035
FF) to 16,529 Euro (108,425 FF). Similar results
were obtained by sensitivity analysis on the cost of
minor stroke.
The risk of major bleeding was also subject to a
sensitivity analysis, where this risk was doubled
compared to base case. The resulting change in to-
tal cost is however, modest (see Table 8).
Two other cost items were associated with un-
certainty. Firstly, the annual treatment cost for
congestive heart failure which has been calculated
on the basis of annual data for France, and sec-
ondly, the number of atrial fibrillation related vis-
its and hospitalizations, which were derived from
an expert consensus panel.
The impact of varying the annual treatment
cost of congestive heart failure on overall costs is
shown in Table 8. An increase or decrease by 30%
of the CHF cost induces a 1498 Euro (9827 FF)
difference in the total costs.
In the third round of the Delphi consensus pro-
cedure, the experts were asked to assign a validity
score to each result. This validity score indicates
the possible divergence from actual country aver-
ages. For example a validity score of two indicates
that the given estimate can diverge with 10–20%
from the actual average. For visits and hospitaliza-
tions, the average validity score reported by the
experts was 2.17, indicating a relative divergence
of 23.4%. We applied this divergence rate in the
sensitivity analysis, the results of which are shown
in Table 8 as well. Again, a variation of 
 

 
1490
Euro (9774 FF) is observed.
Finally, a second order Monte Carlo analysis
was conducted. In this analysis, all applied sto-
chastic clinical variables were distributed accord-
ing to a normal distribution, and the above men-
tioned deterministic cost related variables were
distributed according to an uniform (flat) distribu-
tion between their respective extremes. The result-
ing standard deviation of the result, was 9681
Euro (63,503 FF). Such as figure is of interest for
calculating sample sizes of prospective compara-
tive cost studies.
 
Supplementary Analysis
 
A separate analysis was performed distinguishing
persistent from paroxysmal atrial fibrillation, based
on the following differences:
• Cardioversion is only performed in cases of
persistent atrial fibrillation.
• The prevalence of congestive heart failure is
higher in persistent than paroxysmal atrial fi-
brillation. As a proxy for CHF prevalence, rates
of 85% and 45%, respectively, were applied,
the proportion of patients reported as having
demonstrable cardiac disease [9].
The results of analyzing the model for each type
or arrhythmia are shown in Table 9. The total cost
for persistent atrial fibrillation is equal to 20,340
 
Table 8
 
Total 5-year management cost with sensitivity 
analysis on cost of congestive heart failure (CHF) and
follow-up visits
 
Factor analyzed
% variation
applied
Lower
estimate
Upper
estimate
Optimal anticoagulants use 30–70 103,374 105,408
Risk reduction aspirin 54–18 103,807 106,653
Risk for bleeds 100–200 105,230 107,371
Cost of stroke 70–130 102,035 108,425
Cost of CHF 70–130 95,403 115,057
Cost of visits 77–123 95,456 115,003
 
Table 9
 
Differential cost for persistent and paroxysmal 
atrial fibrillation
 
Persistent Afib Paroxysmal Afib
Drugs 11,003 11,418
Tests 5,679 5,838
Stroke 11,840 10,649
CHF 50,612 26,802
Physicians and hospitalizations 50,077 39,968
Sudden death 1,502 1,155
Cardioversion 2,711 0
Total cost 133,424 95,829
 
Afib, Atrial fibrillation; CHF, Congestive heart failure.
 Cost of Atrial Fibrillation
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Euro (133,424 FF) and for paroxysmal 14,609 Euro
(95,829 FF).
 
Discussion
 
The incidence of second-line treatment in paroxys-
mal and persistent atrial fibrillation was estimated,
based average 5-year direct medical costs and taking
into account its management as well as associated
risks and comorbidity. To our knowledge, such an
analysis has not been conducted previously. Accord-
ing to calculations, the presence of congestive heart
failure incurred the largest proportion of costs, fol-
lowed by stroke, and the pharmacological treatment
of atrial fibrillation. Thus, atrial fibrillation manage-
ment places high demands on medical resources
mainly through its comorbidity and complications.
This is also illustrated by the cost difference between
persistent and paroxysmal atrial fibrillation, which is
largely due to the different prevalence of congestive
heart failure in both patient groups.
These results therefore suggest that initiatives
aiming at a cost reduction of atrial fibrillation man-
agement should concentrate mainly on prevention
or reduction of long-term risks and comorbidity.
With regard to the management of stroke, several
studies have evaluated costs and cost-effectiveness
of anticoagulation therapy, which has become the
treatment of choice and has been proven cost ef-
fective [27,37]. Since this analysis included the use
of anticoagulants in the majority of patients, within
this population at risk there is probably limited
flexibility for cost reduction at the level of stroke
prevention. The exception would be, for instance,
through the development of newer anticoagulants
with a broader therapeutic margin, which would
significantly reduce bleeding complications and
follow-up costs. As a nonpharmacologic alterna-
tive for eliminating the factors underlying the in-
creased stroke risk, i.e., the arrhythmia and car-
diac impairment, catheter ablation may gain interest
in the future.
Several reports have recently concentrated on
the costs and cost-effectiveness of different man-
agement strategies for heart failure [34], the major
cost component in our analysis. Specifically, strat-
egies that may reduce the number of hospital ad-
missions for heart failure have a large impact on
its overall costs [12,38], and as illustrated by our
model, on overall management costs in atrial fi-
brillation. Taking into account the mutual causal-
ity between atrial fibrillation and heart failure, the
ultimate goal of treating atrial fibrillation, restor-
ing sinus rhythm, can be expected to reduce costs
related both to the arrhythmia and coexistent car-
diac impairment.
New technologies such as catheter ablation tech-
niques [39,40], if they prove effective and safe,
may achieve these goals in patients with paroxys-
mal or persistent atrial fibrillation [41].
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Dr. A. Pisapia, Fondation Saint Joseph, Marseille; Dr. R.
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